Equity Capital Markets

Avalo Therapeutics

05/26
s
Piper Sandler served as bookrunner for Avalo Therapeutics on its CMFO
Sub-Type
CMFO
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
$150.0 Million
e
Personalis, Inc.
ATM Program Common Stock
Joint Placement Agent
s
Avalo Therapeutics
Confidentially Marketed Follow-On
Active Bookrunner
$5.0 Billion
k
Pershing Square
Initial Public Offering
Co-Manager
e
Nektar Therapeutics
Follow-On Offering
Active Bookrunner
$65.2 Million
s
Southern First Bancshares
Follow-On Offering
Sole Bookrunner
d
Allogene Therapeutics, Inc.
Follow-On Offering
Passive Bookrunner
$450.0 Million
e
Atlas Energy Solutions
Convertible Senior Notes
Passive Bookrunner
e
Tamboran Resources
Confidentially Marketed Follow-On Offering
Co-Manager
w
Inovio Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Financial Advisor
s
HMH Holding Inc.
Initial Public Offering
Joint Bookrunner
w
Flowco
Confidentially Marketed Follow-On Offering
Lead Bookrunner
$150.0 Million
e
Aardvark Therapeutics
ATM Program Common Stock
Sole Placement Agent
e
CytomX Therapeutics Inc.
Follow-On Offering
Active Bookrunner
$538.0 Million
s
MiniMed Inc.
Initial Public Offering
Passive Bookrunner
$413.7 Million
d
Nurix
ATM Program Common Stock
Sole Placement Agent
3
Medline Industries
Follow-On
Passive Bookrunner

© 2026 Piper Sandler Companies. Since 1895. All rights reserved.